Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Antibody–drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the
potency of highly cytotoxic agents, potentially reducing the severity of side effects by …

Background The prognosis for patients with relapsed or refractory diffuse large B-cell
lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor …

PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging,
bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells …

Monoclonal antibodies constitute a promising class of targeted anticancer agents that
enhance natural immune system functions to suppress cancer cell activity and eliminate …

Abstract In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene
ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy …

The large number of emerging antibody-drug conjugates (ADCs) for cancer therapy has
resulted in a significant market 'boom', garnering worldwide attention. Despite ADCs …

In the last decade, a better understanding of the molecular pathogenesis of B-cell non-
Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as …

The standard of care treatment strategy for patients with relapsed or refractory large B-cell
lymphoma (LBCL) has been high-dose chemotherapy followed by autologous stem cell …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …